Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Esperion Therapeutics, Inc. (NASDAQ: ESPR)
ESPR Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
10.60%
Analyst Rating:
BUY
Analyst Forecast (1yr):
134.40%
ESPR Stock Analysis
ESPR
PE Ratio:
ESPR
PEG Ratio:
ESPR
Forward EPS Growth (12 month):
400.00%
ESPR
PS Ratio:
1.6
ESPR
PSG Ratio:
0.1
ESPR
Forward Revenue Growth (12 month):
15.50%
ESPR Articles
No data was found